http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박상형,김가희,김민준,김규원,박정빈,백지은,배준화,홍승욱,황성욱,양동훈,예병덕,변정식,명승재,양석균 연세대학교의과대학 2024 Yonsei medical journal Vol.65 No.5
Purpose: This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. Materials and Methods: We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies. Results: This study included a total of 53 patients (ulcerative colitis, 41; Crohn’s disease, 6; and gastrointestinal Behçet’s disease, 6). Among them, 15 patients were receiving biologics or small molecules and 38 were not. During a mean follow-up of 119 months, the proportion of patients experiencing severe infections was significantly higher in those treated with biologics or small molecules than in those not treated. However, other safety outcomes (e.g., malignancies, adverse events, including organizing pneumonia or hepatic failure, and death) were not different between the two groups. Kaplan–Meier curve analysis revealed no significant difference in the safety outcome rate related to the use of biologics or small molecules. During follow-up, eight patients underwent bowel resections for IBD. The rate of bowel resection was not different between the two groups. Conclusion: The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.
박종범 ( Bak Jong Beom ),양석균 ( Yang Seog Gyun ),명승재 ( Myeong Seung Jae ),변정식 ( Byeon Jeong Sig ),이윤정 ( Lee Yun Jeong ),이진혁 ( Lee Jin Hyeog ),정훈용 ( Jeong Hun Yong ),홍원선 ( Hong Won Seon ),김진호 ( Kim Jin Ho 대한소화기학회 2004 대한소화기학회지 Vol.43 No.1
Background/Aims: The aim of this study was to evaluate the clinical characteristics and course of Korean patients with Crohn`s disease (CD). Methods: A total of 113 patients who were newly diagnosed as having CD at the Asan Medical Center between October 1989 and December 2001 were included. Results: The male to female ratio was 1.9:1 and the mean age at diagnosis was 24.2±7.8 years. The disease location was the small bowel in 19.5%, the large bowel in 11.5%, and the both small and large bowels in 69.0% of the patients. Empirical anti-tuberculous medications were administered to 53 cases (46.9%). Major complications of CD were intestinal obstruction (25.7%) and perianal fistula (42.5%). The cumulative remission rate was 75.7% at 1 year and 80.7% at 3 years from diagnosis. The cumulative relapse rate was 30.7% at 1 year and 53.0% at 3 years from remission. The cumulative operation rate was 11.5% at 1 year and 13.1% at 3 years from diagnosis. Conclusions: There are no differences in the remission and recurrence rates between Korean and Western patients with CD. Although the cumulative operation rate seems to be lower in Korea than in Western countries, the cause of the difference is uncertain. Further studies are needed to determine the characteristics of CD in Korea. (Korean J Gastroenterol 2004;43:8-17)
박종범 ( Jong Beom Park ),양석균 ( Suk Kyun Yang ),명승재 ( Seung Jae Myung ),장혜숙 ( Hye Sook Chang ),정훈용 ( Hwoon Yong Jung ),홍원선 ( Weon Seon Hong ),김진호 ( Jin Ho Kim ),민영일 ( Young Il Min ) 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
<목적> 크론병은 위장관 전체를 침범하는 질환으로 국내에서도 그 빈도가 점차 증가하고 있다. 그렇지만, 그 발명 빈도는 서구에 비해 드물며, 그 임상 경과에 대해서도 알려진 바가 드물다. 이에 저자들은 서울중앙병원에서 처음으로 진단된 크론병 환자들을 대상으로 하여 진단 당시의 임상 양상과 경과를 알아 보고자 하였다. <방법> 1989년 10월부터 2001년 9월까지 서울중앙병원 염증성 장질환 클리닉에 등록된 267예의 크론병 환자 중 서울중앙병원에서 처